Naproxcinod: Phase III data

A pre-specified pooled analysis of 2,734 OA patients from 3 Phase III trials (Studies 301 and 302 to treat OA of the knee and Study 303 to treat OA of the hip) showed that both 375 and 750 mg twice-da...